Noema Pharma extends its series B funding to $147M, advancing phase 2 trials for CNS disorders like Tourette syndrome, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback